Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Allergan’s Ophthalmology Focus Grows Beyond Restasis And Glaucoma

Feb 04 2017

• By Mandy Jackson

Eye

Related Content

Can Slow Selling Heart Drug Entresto Perk Up In 2017? Novartis Hopes So

Jan 25 2017

INTERVIEW: Bausch & Lomb eyes market listing as acquisition offers roll in

Jan 09 2013

Valeant confirms $8.7bn purchase of Bausch + Lomb

May 28 2013

Bausch & Lomb IPO to be one of 2013's largest

Mar 26 2013

JPM Parting Shots: Immuno-Oncology Plans For Regeneron, Incyte, Molecular Partners

Feb 16 2016

Allergan's Back In The (M&A) Saddle Again Post Pfizer Breakup

Apr 07 2016

Actavis renamed as Allergan

Jun 17 2015

Beyond Restasis: Allergan buys Oculeve dry eye device

Jul 07 2015

Actavis will become Allergan to emphasize branded pharma focus

Feb 19 2015

Debt-laden Valeant Sells Its Assets, More Divestments Likely

Jan 10 2017

J.P. Morgan Notebook Day 2: Bristol Humbled By Competition, Sanofi’s Sarilumab Ready For Review, Justifying Spinraza’s Price And More

Jan 11 2017

Related Companies

Allergan plc

Allergan plc

Allergan, Inc.

Molecular Partners AG

Roche Holding AG

Genentech, Inc.

Novartis AG

Regeneron Pharmaceuticals, Inc.

Bayer AG

Takeda Pharmaceutical Co. Ltd.

Allergan plc

Bausch Health Companies Inc.

Additional Topics

Business Strategies Companies Commercial Ophthalmic BioPharmaceutical

More from Strategy

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.